CIK 0001750149 · Non-accelerated filer<br>Smaller reporting company
Inhibikase Therapeutics, Inc.
Sign in to watch- Ticker
- IKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 263407249
- Phone
- (302) 295-3800
- Business address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Munshi Amit Director | Grant or award · Stock Option (Right to Buy) | +116,585 | 116,585 | ||
| 2025-02-14 | Canner David Director | Grant or award · Stock Option (Right to Buy) | +22,640 | 22,640 | ||
| 2025-02-14 | Canner David Director | Grant or award · Stock Option (Right to Buy) | +116,585 | 116,585 | ||
| 2025-02-14 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +39,620 | 39,620 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +21,854 | 21,854 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +3,780 | 3,780 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +6,667 | 6,667 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +6,667 | 6,667 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-01-21 | Lees-Rolfe Garth Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −5,834 | 0 | ||
| 2025-01-21 | Lees-Rolfe Garth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +5,834 | 5,834 | ||
| 2025-01-21 | Lees-Rolfe Garth Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −90,000 | 0 | ||
| 2025-01-21 | Lees-Rolfe Garth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Returned to the company · Stock Option (Right to Buy) | −21,854 | 0 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +21,854 | 21,854 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Returned to the company · Stock Option (Right to Buy) | −1,138 | 0 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +1,138 | 1,138 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Returned to the company · Stock Option (Right to Buy) | −3,780 | 0 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +3,780 | 3,780 | ||
| 2025-01-21 | BERMAN DENNIS N Director | Returned to the company · Stock Option (Right to Buy) | −6,667 | 0 |
Page 3 of 9 · 163 trades